---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004547"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:10:00.897415+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amylyx prices 17.1M-share public offering at $3.50/sh for ~$56.9M net proceeds

## Summary
- Offering of 17,142,857 common shares at $3.50 per share, with 30-day option for up to 2,571,428 additional shares.
- Net proceeds expected to be ~$56.9 million ($65.5 million if over-allotment exercised in full).
- Closing expected January 13, 2025; proceeds to fund commercialization prep, pipeline, working capital.
- Underwriting agreement includes customary representations, warranties, and market standoff provisions.

## SEC filing metadata
- accession: 0001193125-25-004547
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312525004547/0001193125-25-004547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312525004547/d917502d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004547
- JSON: https://secwatch.observer/filing/0001193125-25-004547.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.